Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06184360 · ClinicalTrials.gov registry record
Real-world Evaluation of BEOVU (Brolucizumab) Effectiveness and Durability for Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD)
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 2,079
- Enrollment target
NCT06184360 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 2,079 participants.
The verdict
NCT06184360 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 2,079 participants
- Enrollment target
Study Summary
This was a retrospective, observational cohort study. Data were analyzed from the Intelligent Research in Sight (IRIS) registry from October 8, 2019, through November 26, 2021, with a follow-up period of 12 months following the first brolucizumab injection (index date).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,079 participants |
| Start Date | 2022-05-31 |
| Est. Completion | 2022-12-16 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06184360
The ClinicalTrials.gov registry entry for NCT06184360 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2,079 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT06184360 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06184360 about?
NCT06184360 is a clinical study titled "Real-world Evaluation of BEOVU (Brolucizumab) Effectiveness and Durability for Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD)". This was a retrospective, observational cohort study. Data were analyzed from the Intelligent Research in Sight (IRIS) registry from October 8, 2019, through November 26, 2021, with a follow-up period of 12 months following the first brolucizumab injection (index date).
What is the current status of trial NCT06184360?
This trial is currently completed. The enrollment target is 2,079 participants. The study started on 2022-05-31. Estimated completion is 2022-12-16.
Who is sponsoring clinical trial NCT06184360?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.